Clinical Trials Logo

Ulcer clinical trials

View clinical trials related to Ulcer.

Filter by:

NCT ID: NCT05213234 Recruiting - Ulcerative Colitis Clinical Trials

Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis

Start date: July 9, 2021
Phase: N/A
Study type: Interventional

The hypothesis of this study is that appropriate time of day of administration of oral, once daily 5-ASA therapy in alignment with the host circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-ASA levels. All subjects will be randomized to once daily 5-ASA medications at two different times of the day: between 06:00 - 10:00 h or 18:00 - 22:00 h. Three disease assessments will performed at: 1) enrollment just before randomization; 2) month 3, at the completion of first arm (Condition 1), and 3) month 6, after completion of the second arm (Condition 2). During these study time points, participants will be asked to complete questionnaires, track their 5-ASA medication usage, provide a stool sample, blood draw, urine test, wear a watch to measure sleep patterns, and complete a flexible sigmoidoscopy.

NCT ID: NCT05205603 Recruiting - Ulcerative Colitis Clinical Trials

Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis

Start date: January 15, 2022
Phase: Phase 4
Study type: Interventional

Endocopic remission rates of moderate to severe ulcerative colitis are low. Biologics including Vedolizumab, infliximab, and adalimumab are effective in induction and maintainence of ulcerative colitis. The role of 5-ASA in promoting a higher rate of endocsopic remission is unclear. We aim to evaluate the efficacy of combination of 5-ASA and biologics in treating ulcerative colitis.

NCT ID: NCT05204784 Recruiting - Systemic Sclerosis Clinical Trials

Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis

RHEACT
Start date: February 28, 2022
Phase: N/A
Study type: Interventional

In this feasibility study, we aim to explore therapeutic Rheopheresis (RheoP) as a novel treatment option for SSc-associated Raynaud's phenomenon and/or digital ulcers and compare it to the standard of care treatment (intravenous iloprost. RheoP has been used for RP/DU with some success in observational studies, nevertheless, the optimal treatment modality, duration, or frequency of RheoP (and PEX in general) in SSc has not been established as of yet.

NCT ID: NCT05194007 Recruiting - Clinical trials for Ulcerative Colitis Chronic Moderate

Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease

Start date: February 19, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a pilot, prospective, double-blinded, two-arm, randomized controlled trial of the efficacy of Frondanol in comparison to placebo in decreasing bowel inflammation in patients with a clinical diagnosis of inflammatory bowel disease who are in remission and on standard of care treatment.

NCT ID: NCT05189470 Recruiting - Diabetes Clinical Trials

Inforatio Technique to Promote Wound Healing of Diabetic Foot Ulcers

Start date: March 10, 2022
Phase: N/A
Study type: Interventional

This randomized clinical trial will examine the effect of inforatio technique on healing of diabetic foot ulcers (DFUs). Inforatio technique is a novel procedure developed by the research group. The definition of inforatio technique is application of small cuts in wound beds with punch biopsy tools without involving surrounding epithelia. The aim is to initiate an acute inflammatory response that will promote healing of the ulcers.

NCT ID: NCT05189327 Recruiting - Clinical trials for Ulcerative Colitis Chronic

Noninterventional Observational Prospective Longitudinal Study of the Incidence of Ulcerative Colitis and Crohn's Disease Among the Adult Population of the Republic of Kazakhstan

NUCaCD
Start date: December 10, 2021
Phase:
Study type: Observational [Patient Registry]

The NUCaCD study aims to develop a reliable registry of patients suffering inflammatory bowel diseases in the Republic of Kazakhstan.

NCT ID: NCT05186623 Recruiting - Ulcerative Colitis Clinical Trials

Prediction Model for Response to Biologics and Small Molecular Agent for UC

Start date: February 5, 2022
Phase:
Study type: Observational [Patient Registry]

This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.

NCT ID: NCT05181137 Recruiting - Ulcerative Colitis Clinical Trials

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Start date: November 5, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.

NCT ID: NCT05176366 Recruiting - Ulcerative Colitis Clinical Trials

Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis

Start date: December 19, 2022
Phase: Phase 1
Study type: Interventional

Protocol Summary - Title: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory ulcerative colitis. - Short Title: ExoFlo for ulcerative colitis - Phase: 1 - Methodology: Open label - Study Duration: 24 months - Subject Participation: 58 weeks - Single or Multi-Site: Multi-Site

NCT ID: NCT05170984 Recruiting - Diabetic Foot Ulcer Clinical Trials

MAtrix Therapy for Hard-to-heal ChrOnic Wounds

MATHCOW
Start date: February 10, 2022
Phase: N/A
Study type: Interventional

CACIPLIQ20® is currently a class III CE marked medical device available in various European and non-European countries, and currently primarily used in managing hard-to-heal wounds. This study is a prospective and standardized recording of patients' data followed in real-life conditions to appreciate the benefits of a therapeutic strategy including CACIPLIQ20® use. It also aims at collecting data to follow-up the device's efficacy and safety and estimate its cost-effectiveness.